Glucagon like peptide 1 receptor agonists in patients with inflammatory bowel disease: safety, clinical effectiveness and anti-inflammatory mechanisms
Frontiers in Gastroenterology · 21.08.2026 · 5
DOI: 10.3389/fgstr.2026.1864456 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Frontiers in Gastroenterology, online erschienen am 21.08.2026. Verfasst von Shannon Fernando und 9 weiteren Autor:innen. Beteiligte Einrichtung: Sidney Kimmel Medical School, Thomas Jefferson, University Hospital, Philadelphia, PA, United States. Die Arbeit nennt 59 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Introduction
The prevalence of obesity among patients with inflammatory bowel disease (IBD) continues to rise and is associated with adverse IBD outcomes and diminished treatment response. This study reviews the clinical safety and efficacy of glucagon-like peptide-1 receptor agonists (GLP-1RA) in patients with IBD and comorbid obesity and explores their theorized anti-inflammatory mechanisms.
Methods
Published articles through July 2026 were identified via a PubMed search for a narrative review using terms related to GLP-1RA, IBD, safety, effectiveness, and outcomes. Data extraction focused on GLP-1RA intervention details, IBD-related outcomes and inflammatory markers, and proposed anti-inflammatory mechanisms.
Results
GLP-1RA therapy promotes weight loss in patients with IBD comparable to the general population (about 16 pounds over 18 months). The most frequently reported adverse effects are gastrointestinal, often limiting treatment continuity. Most studies report no significant differences in hospitalization, surgery, steroid use or IBD medication adjustments, and some reported improvement in these outcomes. Data on endoscopic disease activity is limited. Inconsistent effects of GLP-1RA on inflammatory serum biomarkers were noted, with reductions in CRP but no consistent changes in fecal calprotectin.
Discussion
Addressing obesity in patients with IBD is an emerging clinical priority. GLP-1RA therapy demonstrates efficacy in promoting weight loss, improving glycemic control, and reducing systemic inflammation, which may benefit IBD disease activity. Longitudinal studies are required to clarify the long-term impact of GLP-1RA on clinical and endoscopic outcomes in IBD.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Sidney Kimmel Medical School, Thomas Jefferson, University Hospital, Philadelphia, PA, United States.
- Department of Internal Medicine, Thomas Jefferson, University Hospital, Philadelphia, PA, United States.
- Division of Gastroenterology, Hepatology, and Nutrition, Allegheny Health Network, Pittsburgh, PA, United States.
- College of Medicine, Drexel University, Philadelphia, PA, United States.
- Division of Gastroenterology and Hepatology, Thomas Jefferson University Hospital, Philadelphia, PA, United States.
- Division of Gastroenterology and Hepatology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, United States.
Zitieren
APA
Fernando, S., Zhao, J., Josloff, K., Zubair, N., Desai, A., Shivashankar, R., Kozuch, P. L., Choudhary, C., Lichtenstein, G., & Sehgal, P. (2026). Glucagon like peptide 1 receptor agonists in patients with inflammatory bowel disease: safety, clinical effectiveness and anti-inflammatory mechanisms. Frontiers in Gastroenterology, 5. https://doi.org/10.3389/fgstr.2026.1864456
Vancouver
Fernando S, Zhao J, Josloff K, Zubair N, Desai A, Shivashankar R, et al. Glucagon like peptide 1 receptor agonists in patients with inflammatory bowel disease: safety, clinical effectiveness and anti-inflammatory mechanisms. Frontiers in Gastroenterology. 2026;5. doi:10.3389/fgstr.2026.1864456
BibTeX
@article{Fernando2026,
author = {Fernando, Shannon and Zhao, Joy and Josloff, Kevan and Zubair, Nida and Desai, Aakash and Shivashankar, Raina and Kozuch, Patricia L and Choudhary, Cuckoo and Lichtenstein, Gary and Sehgal, Priya},
title = {Glucagon like peptide 1 receptor agonists in patients with inflammatory bowel disease: safety, clinical effectiveness and anti-inflammatory mechanisms},
journal = {Frontiers in Gastroenterology},
year = {2026},
volume = {5},
doi = {10.3389/fgstr.2026.1864456}
}
EUVIMED